Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LEQ506 · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| LEQ506 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| LEQ506 | DRUG | - |
Inclusion Criteria: * Confirmed diagnosis of advanced solid tumor, recurrent or refractory medulloblastoma or locally advanced or metastatic basal cell carcinoma) * Protocol defined laboratory parameters * Performance status ≤ 2 * Patients must have fully recovered from the prior effects of major s...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
LEQ506 is an investigational oral small molecule being studied in adults with advanced solid tumors, including recurrent or refractory medulloblastoma and locally advanced or metastatic basal cell carcinoma. It has been evaluated in a single Phase 1 dose-finding and safety study and is not an approved therapy.
LEQ506 targets SMO, short for Smoothened, a component of the Hedgehog signaling pathway. LEQ506 acts as a SMO antagonist, meaning it is designed to block SMO activity. The Hedgehog pathway is implicated in several tumor types, including basal cell carcinoma and medulloblastoma.
LEQ506 is developed by Novartis AG, which trades under the ticker NVS. Novartis sponsored the Phase 1 dose-finding and safety study of oral LEQ506 in patients with advanced solid tumors.
LEQ506 is in Phase 1 clinical development. It is investigational and has not been approved for any indication. The single Phase 1 trial of LEQ506 has completed, and no active trials of the drug are currently listed.
LEQ506 has been studied in one completed Phase 1 trial, NCT01106508, titled A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid Tumors. It enrolled 57 adults across the United States, Netherlands, Switzerland, and the United Kingdom, and was an uncontrolled study without randomization or blinding.